Nurix Posts Surprise $4.73 Q3 Profit, Defying Loss Expectations
NRIX has more than doubled off its 52-week low of $9.
Summary
Nurix reported third-quarter net income of $549.8M and revenue of $673.1M, with EPS of $4.73, a sharp swing from the $89.5M net loss in Q2. The profit likely reflects the Roche collaboration upfront payment, which was expected to add ~$1.14B in pro-forma cash. This is the first concrete earnings number since the HSR clearance in July and the Gilead research extension in early October. The stock trades at $23 with a $2.3B market cap, so a $4.73 quarterly profit is highly material.
Updates
· SEC 8-K — Nurix's 8-K confirms Q3 net income of $549.8M, revenue of $673.1M, and cash of $1.1B as of August 31, 2026.
At the time of this announcement, NRIX was trading at $23.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $9.00 to $28.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.